^
Association details:
| Biomarker: | AR positive |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 4850: Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
Published date:
05/15/2020
Excerpt:
Anti-proliferative activity of abemaciclib was observed across a panel of PCa cell lines, mainly in hormone receptor positive (AR+) cell lines….these data provide insights on sensitivity of PCa models to abemaciclib and its mode of action, demonstrating the potential of this drug for the treatment of prostate cancer patients.
DOI:
10.1158/1538-7445.AM2020-4850
